8:01AM Rexahn Pharmaceuticals announces Phase II results for Serdaxin as treatment for major depressive disorder - all groups showed an approximate -14 point improvement (RNN) 1.02 : Co announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 mg and 5 mg, to placebo over an 8-week treatment period. Results from the study did not demonstrate Serdaxin's efficacy compared to placebo measured by the Montgomery-Asberg Depression Rating Scale. All groups showed an approximate -14 point improvement in the protocol defined primary endpoint of MADRS. All groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. The study showed Serdaxin to be safe and well tolerated.
Market Data 
Markets 
AI
